Why Expro Group Holdings (XPRO) Is Down 5.0% After Analyst Downgrade On Flat 2026 Outlook - And What's Next

• Earlier in March, Freedom Capital analyst Sergey Pigarev downgraded Expro Group Holdings N.V. to Sell from Hold following its fiscal Q4 2025 results and management’s guidance for flat 2026 revenue amid softer global drilling activity and weaker oil prices.
• The downgrade highlights how Expro’s sensitivity to shifts in drilling demand and commodity prices can quickly influence sentiment around its near-term operating outlook.
• We’ll now examine how this downgrade, rooted in cautious Q1 2026 expectations, may reshape Expro’s existing investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 35 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Expro Group Holdings Investment Narrative Recap

To own Expro today, you need to believe its international and offshore services portfolio can keep generating value even when drilling activity softens and oil prices weaken. The latest downgrade, driven by flat 2026 revenue guidance and cautious Q1 expectations, directly clouds the near term earnings catalyst while reinforcing the key risk that Expro’s results can tighten quickly when customers pull back spending. If you already saw the business as cyclical, this news likely reinforces, rather than reshapes, that view.

The most relevant recent announcement is Expro’s February 19 guidance calling for Q1 2026 revenue of US$360 million to US$370 million and full year 2026 revenue of US$1.60 billion to US$1.65 billion. This relatively flat outlook, following a year in which revenue slipped to US$1.61 billion, sits awkwardly beside the earlier growth focused catalyst of a strong backlog and cost initiatives, and is a key reason why some analysts now frame execution risk more prominently in the short term.

Yet behind the headline downgrade, you should be aware that Expro’s dependence on international and offshore spending could...

Read the full narrative on Expro Group Holdings (it's free!)

Expro Group Holdings' narrative projects $1.7 billion revenue and $83.2 million earnings by 2028. This requires a 0.3% yearly revenue decline and an earnings increase of about $11.9 million from $71.3 million today.

Uncover how Expro Group Holdings' forecasts yield a $14.40 fair value, a 10% downside to its current price.

Exploring Other Perspectives

Compared with the consensus, the most cautious analysts already assumed almost flat annual revenue around US$1.7 billion and earnings of roughly US$82.7 million, so this downgrade may push their already more pessimistic view on execution risk and margins even further, reminding you that reasonable people can look at the same data and reach very different conclusions.

Explore 2 other fair value estimates on Expro Group Holdings - why the stock might be worth 10% less than the current price!

The Verdict Is Yours

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Expro Group Holdings research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Expro Group Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Expro Group Holdings' overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• We've uncovered the 15 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.
• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com